首页> 外文期刊>The Turkish journal of pediatrics >Pulmonary complications following hematopoietic stem cell transplantation in children
【24h】

Pulmonary complications following hematopoietic stem cell transplantation in children

机译:儿童造血干细胞移植后肺部并发症

获取原文
获取原文并翻译 | 示例
       

摘要

Pediatric data about early or long-term pulmonary complications of hematopoietic stem cell transplantation (HSCT) are limited. Here we aimed to evaluate children who were treated with HSCT in the last 10 years and developed pulmonary complications following HSCT and to determine their risk factors associated with pulmonary complications.In this retrospective study, we evaluated 195 patients for the development of pulmonary complications after HSCT within a 10 years of period. Pulmonary complications developed in 71 (36.4%) patients. Of the 71 patients who had pulmonary complications, 60 had one pulmonary complication, 11 had two pulmonary complications. Pulmonary complications were diagnosed as early in 42 (51.2%) and late in 40 (48.8%) episodes. Pulmonary complications were infectious in 28 (34.1%), noninfectious in 20 (24.4%) and both infectious and nonfectious in 34 (41.5%) episodes. Pulmonary complications developed significantly more frequently in patients with malignancy, congenital immune deficiency and with at least one pulmonary disease before HSCT. The number of patients who had myeloablative conditioning regimen was significantly higher in the group of patients without pulmonary complications than the group with pulmonary complications. However, in multivariate analysis, none of these variables were shown to be effective in predicting pulmonary complications after HSCT (p>0.05). During follow up, 54 (65.8%) episodes recovered, 20 (24.3%) episodes resulted with death due to pulmonary complications, 6 (7.3%) episodes had chronic pulmonary disease (bronchiolitis obhterans (BO) and bronchiolitis obliterans organizing pneumonia (BOOP)); 2 patients (each patient with one episode) were lost to follow up. In conclusion; identifying children who are at risk for severe pulmonary complications and close longitudinal follow-up after HSCT by pediatric pulmonologists is mandatory to increase survival and life quality of these patients.
机译:关于造血干细胞移植(HSCT)早期或长期肺部并发症的儿科数据有限。我们的目的是评估在过去10年中接受HSCT治疗并在HSCT后出现肺部并发症的儿童,并确定他们与肺部并发症相关的风险因素。在这项回顾性研究中,我们评估了195例HSCT术后10年内肺部并发症的发生情况。71例(36.4%)患者出现肺部并发症。在71例有肺部并发症的患者中,60例有一种肺部并发症,11例有两种肺部并发症。肺部并发症的早期诊断为42例(51.2%),晚期诊断为40例(48.8%)。肺部并发症感染性28例(34.1%),非感染性20例(24.4%),感染性和非感染性34例(41.5%)。在HSCT前患有恶性肿瘤、先天性免疫缺陷和至少一种肺部疾病的患者中,肺部并发症的发生率明显更高。无肺部并发症组接受清髓性预处理方案的患者人数明显高于有肺部并发症组。然而,在多变量分析中,这些变量均不能有效预测HSCT术后肺部并发症(p>0.05)。随访期间,54例(65.8%)发作恢复,20例(24.3%)发作因肺部并发症导致死亡,6例(7.3%)发作有慢性肺部疾病(obhterans细支气管炎(BO)和闭塞性细支气管炎组织性肺炎(BOOP));2名患者(每名患者有一次发作)失去随访。总之;儿童肺科医生必须确定有严重肺部并发症风险的儿童,并在HSCT后进行密切的纵向随访,以提高这些患者的生存率和生活质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号